Jiabao Renhe is an integrated reproductive-genetics services company founded in 2011 that offers one-stop solutions across assisted reproduction, genetic testing and eugenics. Its product portfolio includes NGS-based testing products and non-sequencing products such as equipment, consumables and management software, with efforts to localize various tests. The company was the first domestic adopter of NGS for PGT and has cumulatively tested over 180,000 embryo samples, including more than 43,000 PGT‑M cases; it can detect over 510 single-gene diseases involving roughly 6,100 families and maintains the country’s largest single-gene S‑PGD database. Its PGT‑A reagent has received an NMPA “innovative medical device special approval,” and its wholly owned Jiabao Medical Laboratory obtained CAP certification in 2019. Jiabao Renhe reports broad clinical penetration—its PGT series covers over 80% of mainland China’s PGD‑qualified reproductive centers—and emphasizes low core-client churn. The company plans to use new funding to accelerate R&D of reproductive‑genetics innovation products and to promote its integrated service platform, while expanding from assisting fertility toward broader pre-pregnancy eugenics screening and services. Jiabao Renhe has also launched a public welfare “Love Unlimited Health” fund to support physician education, research translation and aid for underprivileged families.

Total raised

$14M

Funding rounds

1

Latest round

Series B

Latest activity

Aug 2020